Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Vorinostat may stop the growth of cancer cells by interfering with various
proteins needed for cell growth. Monoclonal antibodies, such as gemtuzumab ozogamicin (GO),
can block cancer growth in different ways. GO finds cancer cells and helps kill them by
carrying a cancer-killing substance to them. Giving vorinostat together with gemtuzumab
ozogamicin may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving vorinostat together with gemtuzumab
ozogamicin works in treating older patients with previously untreated acute myeloid leukemia.